Zobrazeno 1 - 10
of 468
pro vyhledávání: '"Sikander, Ailawadhi"'
Autor:
Sikander Ailawadhi, Hans C. Lee, James Omel, Kathleen Toomey, James W. Hardin, Cristina J. Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Prashant Joshi, Ying-Ming Jou, Jorge Mouro, Edward Yu, Rafat Abonour
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell transplant. This analysis investigated the impac
Externí odkaz:
https://doaj.org/article/381d32e080554f2f9c1847e9e8ecb4c7
Autor:
Ricardo D. Parrondo, Betsy R. LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J. Flott, Diedre Arrington, Dustin Chapin, Jade Brown, Saurav Das, Vivek Roy, Asher A. Chanan-Khan, Sikander Ailawadhi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/91c6bdbb2c0244cbb8d319fe7979abc9
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Many studies have documented racial, socioeconomic, geographic, and other disparities for United States (US) patients with multiple myeloma pertaining to diagnosis and frontline management. In contrast, very little is known about disparities
Externí odkaz:
https://doaj.org/article/831b0abdd6fd4c0ebc39d17a82b1623e
Autor:
Matthew J. Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, Mohammed E. Elhaj, Arwa Bohra, Radhika Bansal, Sikander Ailawadhi, Ricardo Parrondo, Saurabh Chhabra, Amit Khot, Suzanne Hayman, Angela Dispenzieri, Francis Buadi, David Dingli, Rahma Warsame, Prashant Kapoor, Morie A. Gertz, Eli Muchtar, Taxiarchis Kourelis, Wilson Gonsalves, S. Vincent Rajkumar, Yi Lin, Shaji Kumar
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients tr
Externí odkaz:
https://doaj.org/article/e937bbbd77af4514829023b80d8a83b4
Autor:
Sikander Ailawadhi, Yaw Adu, Ryan D. Frank, Saurav Das, David O. Hodge, Andre Fernandez, Caitlyn Flott, Jamie Elliott, Ricardo Parrondo, Taimur Sher, Vivek Roy, Asher A. Chanan-Khan
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Abstract Multiple myeloma (MM) therapeutics have evolved tremendously in recent years, with significant improvement in patient outcomes. As newer treatment options are developed, stem cell transplant (SCT) remains an important modality that provides
Externí odkaz:
https://doaj.org/article/89dae84d967e4beb847fa9314239a4a1
Autor:
Benjamin Ackerman, Ryan W. Gan, Craig S. Meyer, Jocelyn R. Wang, Youyi Zhang, Jennifer Hayden, Grace Mahoney, Jennifer L. Lund, Janick Weberpals, Sebastian Schneeweiss, James Roose, Juned Siddique, Omar Nadeem, Smith Giri, Til Stürmer, Sikander Ailawadhi, Ashita S. Batavia, Khaled Sarsour
Publikováno v:
Frontiers in Drug Safety and Regulation, Vol 4 (2024)
Introduction: While randomized controlled trials remain the reference standard for evaluating treatment efficacy, there is an increased interest in the use of external control arms (ECA), namely in oncology, using real-world data (RWD). Challenges re
Externí odkaz:
https://doaj.org/article/c00455226d6749b884e3043112d1c680
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal outcomes with subsequent therapies. Progressive immune dysfunction, parti
Externí odkaz:
https://doaj.org/article/03b1c87e974243fa9e249a680907a338
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9627-9633 (2023)
While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patients with AL amyloidosis have been excluded from trials with these agents due to concerns of underlying autonomic
Externí odkaz:
https://doaj.org/article/cbacf3c75486498daa3e2878b90b9592
Autor:
Sikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Mizba Baksh, Ahsan Rasheed, Saurav Das, Andre J. Fernandez, Aneel Paulus, Asher A. Chanan‐Khan
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19013-19020 (2023)
Abstract Introduction Health information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial‐ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization.
Externí odkaz:
https://doaj.org/article/1a893cfa3efb441eb05f8da1cd56f354
Autor:
Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematologi
Externí odkaz:
https://doaj.org/article/781664a000bf43b0842a034c8f0fd087